Navigation Links
Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Date:5/10/2013

SAN DIEGO, May 10, 2013  /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013, at 2:20 p.m. Pacific Time (5:20 p.m. Eastern Time), at the Encore at the Wynn Las Vegas Hotel in Las Vegas, Nevada.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ® (lorcaserin HCl), Arena's internally discovered drug, is approved in the United States, and is under review for regulatory approval in additional territories. Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland. For more information, visit Arena's website at www.arenapharm.com.

Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ® is a registered trademark of Arena Pharmaceuticals GmbH.

Forward-Looking StatementsCert
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BIOCOM Applauds Arena Pharmaceuticals Commitment to Innovation, Contributions to Southern California Life Science Community
2. Carena Launches 24/7 Virtual Care Delivery Service for Hospital Systems and Primary Care Clinics
3. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
4. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, May 2
5. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
6. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
7. Arena Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
8. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, March 4
9. Proposed Regulatory Uniformity to Boost Venture Capital Investments in Healthcare Arena, Says Frost & Sullivan
10. Arena Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference
11. Arena Pharmaceuticals and Ildong Pharmaceutical Enter Into Co-Development and License Agreement for Temanogrel, a Novel Agent for Thrombotic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... March 2, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, today ... offering of common stock have exercised their option to ... at a price to the public of $11.50 per ... is expected to be $64.8 million, after deducting underwriting ...
(Date:3/2/2015)... , March 2, 2015 Valencia Technologies ... th patient with its radically small device for ... 2015. Valencia,s early results in this randomized, double-blinded, controlled trial ... degree of confidence that it will succeed in a ... its early clinical results, Valencia ...
(Date:3/2/2015)... NEW YORK , March 2, 2015 For the ... million car accidents per year in the U.S. alone (U.S. Census ... goodness most are minor fender benders BUT there are quite a ... due to cabin intrusion, which can obstruct the seatbelt release button ... to avoid being in any serious accidents in their lifetime but ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Underwritten Public Offering of Common Stock 3Valencia Technologies Implants its 48th Patient, Continues Equity Crowdfunding 2New SuperVizor, an Automobile Escape Tool, Ensures the Safety of Drivers and Passengers on the Road 2
... UCB, Inc. today announced an agreement with ... disclosed government investigation into the marketing and promotion of Keppra®, ... were the subject of this investigation occurred more than six ... cooperated fully with the United States since learning of the ...
... A post hoc analysis from the RECOVER study ... Transdermal System) suggested that patients with Parkinson,s disease who ... key markers of mood/cognition, such as taking interest in ... Additional data presented from a one year open ...
Cached Medicine Technology:UCB, Inc. Resolves Investigation of Past Keppra® Marketing and Promotional Activities 2Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinson's Disease 2Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinson's Disease 3Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinson's Disease 4Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinson's Disease 5Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinson's Disease 6
(Date:3/2/2015)... 2015 Cutler Integrative Medicine a leader ... root, gives cutting-edge tips to bring about self-renewal. A ... the body by first cleaning house. According to ... are all Toxic.” Between environmental toxins like heavy metals, ... and our high stress levels, we all have a ...
(Date:3/2/2015)... Surgeons at the Forbes Hospital ... are exploring an innovative use of Google Glass ... Reminder (VIZR), to assist in the care of critically ... a wearable technology with an optical head-mounted display that ... with the Internet via natural language voice commands. , ...
(Date:3/2/2015)... NY (PRWEB) March 02, 2015 ... history of catalyzing private sector activities and investments ... has recently elected four new members to serve ... welcomes Dr. Paul Farmer, Chief Strategist and Co-founder ... at Harvard University; Dr. Huma Abbasi, General Manager ...
(Date:3/2/2015)... March 02, 2015 Market Publishers Ltd ... worked out by Global Industry Analysts Inc and recently ... Market Research Report . Through 2018, the global radiation ... CAGR. The detailed research report suggests a holistic analysis ... therapy equipment as well as covers the top market ...
(Date:3/2/2015)... New York, NY (PRWEB) March 02, 2015 ... & Drug Administration (FDA) warned against the use ... invasive hysterectomies and fibroid removal surgeries, insurer UnitedHealthCare ... require the use of those devices. In a ... said that beginning in April, it would require ...
Breaking Medicine News(10 mins):Health News:Skin and Wellness Power Couple give Quick Tips to Self-Renewal for Spring 2Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 2Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 3Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 2Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 3Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 4Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 5Health News:New Topical Research Reports Prepared by GIA Now Available at MarketPublishers.com 2Health News:New Topical Research Reports Prepared by GIA Now Available at MarketPublishers.com 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 4
... of the 20th anniversary of the record-setting Magnum XL-200 roller ... teaming up with Cedar Point amusement park/resort to hold an ... riders of Magnum,s historic 2009 season.The Red Cross is auctioning ... starting at $75. All riders must be 48 inches ...
... Study in mice finds added benefit from cholesterol-reducing ... -- Drugs that stimulate cells to release cholesterol ... which causes AIDS, a new study suggests. , ... TO-901317 in mice and found that the treatment ...
... link between body fat and cancer identified by a ... could lead to new cancer treatment and prevention strategies. ... nutrition researcher with the Michigan Agricultural Experiment Station, identified ... killer of Americans, in part by examining tissue hormones. ...
... group of arthritidies that share clinical features ... at sites where tendons attach to bone. ... inflammatory bowel-disease-related arthritis, reactive arthritis (ReA) and ... Chlamydia pneumoniae (which are often asymptomatic) frequently ...
... and Other Healthcare ProfessionalsDALLAS, April 30 ... outbreak, T-System, Inc., the nation,s largest provider of ... the release of free downloadable charting templates with ... and Prevention (CDC) guidelines for testing and treatment ...
... a leading manufacturer of cold chain management solutions ... all products that help ensure product efficacy for ... to monitor and record temperature, and can be ... pharmaceuticals.Many vaccines and pharmaceuticals have temperature sensitivity where ...
Cached Medicine News:Health News:Firelands Chapter of the American Red Cross to Auction First Rides on Magnum's 20th Anniversary 2Health News:Cancer-obesity link discovery by MSU researchers could aid prevention efforts 2Health News:Chlamydia may play role in a type of arthritis 2Health News:T-System Releases Free Clinician Swine Flu Templates, Incorporating Updated CDC Interim Guidelines for Diagnosis and Treatment 2Health News:DeltaTRAK Responds to Swine Flu Outbreak With Full Line of Products for Temperature Sensitive Vaccines 2
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: